Innovative Therapeutics Exonate develops cutting-edge non-invasive eye drop treatments targeting retinal vascular diseases such as diabetic retinopathy and diabetic macular oedema, which positions the company to address a significant unmet medical need and expand market share.

Strategic Collaborations Partnered with Janssen Pharmaceuticals since 2020, Exonate has established a strong industry connection that could facilitate co-marketing opportunities, licensing agreements, or joint ventures aimed at bringing innovative ophthalmic therapies to market.

Recent Leadership Expansion The appointment of a new Non-Executive Director in May 2024 suggests an active effort to strengthen governance and attract strategic expertise, making the company more attractive for potential investors, partners, and sales collaborations.

Financial Growth Potential With a current revenue estimate of one to ten million dollars and recent funding rounds totaling nearly two million dollars, Exonate is positioned to grow and scale its sales efforts within ophthalmic healthcare providers and biotech markets.

Market Focus & Technology Utilizing advanced biotech platforms and a focused pipeline on retinal diseases, Exonate offers a unique portfolio for ophthalmology clinics, healthcare distributors, and pharma partners seeking innovative, non-invasive treatments for vision-threatening conditions.